A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
Year: 2024
Type: article
Study design: Clinical Trial
Abstract: BACKGROUND Bimiralisib is a pan-PI3K/mTOR inhibitor demonstrating antitumor efficacy in preclinical models. The objectives of this study were to identify a maximum tolerated dose (MTD), pharmacokinetics (PK), a dosing schedule, and adverse events (AEs) in patients with advanced solid tumors. PATIENTS AND METHODS Patients received oral bimiralisib to determine the MTD of one continuous (once daily) and two intermittent schedules (A: Days 1, 2 weekly; B: Days 1, 4 weekly) until progression or unacceptable AEs occurred. RESULTS The MTD for the continuous schedule was 80 mg, with grade three fatigue as the dose-limiting toxicity (DLT). No MTD was reached with intermittent schedules, with only one DLT in schedule B. PK analysis suggested that 140 mg (schedule A) was within the biologically active dose range and was selected for further exploration. The most frequent treatment-emergent AEs were hyperglycemia (76.2%) in the continuous schedule, and nausea (56-62.5%) in schedules A and B. The most frequent treatment-emergent > grade three AE for all schedules combined was hyperglycemia (28.6%, continuous schedule; 12.0%, schedule A; 12.5%, schedule B). There was one partial response in a head and neck squamous cancer patient with a NOTCH1$^{T1997M}$ mutation. CONCLUSIONS Bimiralisib demonstrated a manageable AE profile consistent with this compound class. Intermittent schedules had fewer > grade three AEs, while also maintaining favorable PK profiles. Intermittent schedule A is proposed for further development in biomarker-selected patient populations.
Authors: Janku, Filip; https://orcid.org/0000-0002-8123-4065, Choong, Grace M, Opyrchal, Mateusz; https://orcid.org/0000-0003-2454-7441, Dowlati, Afshin; https://orcid.org/0000-0003-4535-6839, Hierro, Cinta, Rodon, Jordi, Wicki, Andreas; https://orcid.org/0000-0002-2924-8080, Forster, Martin D, Blagden, Sarah P, Yin, Jun, Reid, Joel M, Muller, Helene, Cmiljanovic, Natasa, Cmiljanovic, Vladimir, Adjei, Alex A
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W7212071044